Status:
TERMINATED
A Study Of Different Doses Of TBC3711 In Patients With Uncontrolled High Blood Pressure Already Taking Medications For High Blood Pressure.
Lead Sponsor:
Pfizer
Conditions:
Resistant Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The study was to determine the safe and effective dose of TBC3711 in patients with uncontrolled high blood pressure while already taking blood pressure medications.
Detailed Description
The study was stopped due to Pfizer (sponsor) decision that the compound would not be involved in any further clinical development for the indication of resistant hypertension on 05 August 2008. This ...
Eligibility Criteria
Inclusion
- Diagnosis of resistant hypertension.
- A stable anti-hypertensive drug regimen for at least 30 days.
Exclusion
- Sustained blood pressure greater than or equal to 180/120 mmHg.
- Required use of thigh cuff for blood pressure readings.
- Uncontrolled diabetes mellitus.
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00272961
Start Date
January 1 2006
End Date
August 1 2008
Last Update
March 5 2013
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Birmingham, Alabama, United States, 35294-2041
2
Pfizer Investigational Site
Mobile, Alabama, United States, 36608
3
Pfizer Investigational Site
Atlanta, Georgia, United States, 30309
4
Pfizer Investigational Site
Augusta, Georgia, United States, 30904